DrugPatentWatch Database Preview
AVASTIN Drug Profile
» See Plans and Pricing
Summary for Tradename: AVASTIN
| Patents: | 1011 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for AVASTIN |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for AVASTIN |
Recent Clinical Trials for AVASTIN
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| MedSIR | Phase 2 |
| Elizabeth Buchbinder | Phase 2 |
| Vascular Biogenics Ltd. operating as VBL Therapeutics | Phase 2 |
Recent Litigation for AVASTIN
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Genentech, Inc. v. Samsung Bioepis Co. Ltd. | 2020-06-28 |
| Ravgen, Inc. v. Natera, Inc. | 2020-06-01 |
| Ravgen, Inc. v. PerkinElmer Inc. | 2020-06-01 |
PTAB Litigation
| Petitioner | Date |
|---|---|
| 2018-01-08 | |
| 2018-01-05 | |
| 2017-12-20 |
Pharmacology for AVASTIN
Company Disclosures: US Patents for AVASTIN
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | Athena Neurosciences, Inc. (South San Francisco, CA) | 2014-01-25 | RX | Orphan | company |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | Biogen, Inc. (Cambridge, MA) | 2020-08-05 | RX | Orphan | company |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 002 | 2004-02-26 | Start Trial | Athena Neurosciences, Inc. (South San Francisco, CA) | 2014-01-25 | RX | Orphan | company |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 002 | 2004-02-26 | Start Trial | Biogen, Inc. (Cambridge, MA) | 2020-08-05 | RX | Orphan | company |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for AVASTIN
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | IMMATICS BIOTECHNOLOGY GMBH (Tuebingen, DE) | 2035-03-27 | RX | Orphan | search |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (Seoul, KR) | 2032-09-12 | RX | Orphan | search |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE) | 2035-12-11 | RX | Orphan | search |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | Oncomatryx Biopharma, S.L. (Derio, ES) | 2034-02-06 | RX | Orphan | search |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | TARIS Biomedical LLC (Lexington, MA) | 2035-03-30 | RX | Orphan | search |
| Genentech | AVASTIN | bevacizumab | VIAL; INTRAVENOUS | 125085 | 001 | 2004-02-26 | Start Trial | GENENTECH, INC. (South San Francisco, CA) | 2033-03-13 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for AVASTIN
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20130115302 | Start Trial |
| China | 107849144 | Start Trial |
| Canada | 2603853 | Start Trial |
| China | 105254634 | Start Trial |
| South Korea | 20100090683 | Start Trial |
| Mexico | 346361 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for AVASTIN
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 122015000061 | Germany | Start Trial | PRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826 |
| 93138 | Luxembourg | Start Trial | PRODUCT NAME: RITUXIMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20140326 |
| 300673 | Netherlands | Start Trial | PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220 |
| 132014902271575 | Italy | Start Trial | PRODUCT NAME: PACLITAXEL LEGATO ALL'ALBUMINA FORMULATO IN NANOPARTICELLE(ABRAXANE); AUTHORISATION NUMBER(S) AND DATE(S): EU/01/07/428, 20131220 |
| 122006000043 | Germany | Start Trial | PRODUCT NAME: NATALIZUMAB; NAT. REGISTRATION NO/DATE: EU /1/06/346/001 20060627; FIRST REGISTRATION: EU EU/1/06/346/001 20060627 |
| 92642 | Luxembourg | Start Trial | PRODUCT NAME: POMALIDOMIDE ET SES SELS, SOLVATES, HYDRATES OU STEREOISOMERES PHARMACEUTIQUEMENT ACCEPTABLES QUI EN DERIVENT (IMNOVID); FIRST REGISTRATION DATE: 20130805 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
